---
title: "B Lymphocytes in LADA: Immunometabolic Heterogeneity and Precision Therapeutic Perspectives"
id: "pubmed-42661296"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42661296"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42661296/"
doi: "10.1002/dmrr.70224"
published_at: "2026-09-01T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# B Lymphocytes in LADA: Immunometabolic Heterogeneity and Precision Therapeutic Perspectives
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42661296
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42661296/)
- **DOI:** [10.1002/dmrr.70224](https://doi.org/10.1002%2Fdmrr.70224)
- **Published At:** 2026-09-01T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Latent autoimmune diabetes in adults (LADA) is a heterogeneous autoimmune diabetes with adult onset, islet autoantibodies, and slower progression to insulin dependence than classical type 1 diabetes. - LADA lies at the interface of **type 1** and **type 2 diabetes**, driven by interactions among genetic susceptibility, immune dysregulation, and metabolic stress. - While autoreactive T cells are central to β‑cell destruction, accumulating evidence indicates **B lymphocytes** have broader roles beyond autoantibody production, including antigen presentation, cytokine secretion, and modulation of T cell responses. - Circulating B cell perturbations reported in LADA include expansion of memory B cells and plasmablasts and impairment or reduction of regulatory B cells; the causal direction of these changes (primary driver vs secondary response) remains unresolved. - Metabolic and immunometabolic stress in β cells can cause endoplasmic reticulum dysfunction and neoantigen formation, promoting enhanced antigen presentation and shaping adaptive immune responses, including B cell activation and selection. - **B lymphocytes** act as immunological amplifiers within a feed‑forward immunometabolic network: integrating β‑cell–derived antigenic signals, presenting antigen to CD4+ T cells via MHC class II, producing islet‑specific autoantibodies, and secreting pro- and anti‑inflammatory cytokines. - Molecular profiling has identified distinct LADA endotypes along a spectrum stratified by **GADA** (glutamic acid decarboxylase antibody) titres, with high‑GADA cases showing stronger autoimmune signatures and faster β‑cell decline, and low‑GADA cases showing greater metabolic overlap and slower progression. - These insights justify exploration of precision medicine strategies that target B cell functions to preserve residual β‑cell function, but such interventions remain investigational according to the source. - The review emphasizes heterogeneity, mechanistic links between β‑cell stress and adaptive immunity, and the need for further research to clarify B cell causality and to translate endotype classification into targeted therapies.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42661296/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42661296%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42661296/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42661296/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42661296/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/af7de7da-df5d-41c6-8de4-8c266af8ccfb/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42661296/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42661296/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42661296/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42661296%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42661296%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42661296/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42661296/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42661296/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42661296/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Wiley full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--media.wiley.com-assets-7388-69-wiley-full-text.png) Wiley ](https://doi.org/10.1002/dmrr.70224 "See full text options at Wiley")[ Free PMC article ](https://pmc.ncbi.nlm.nih.gov/articles/pmid/42661296/ "Free full text at PubMed Central") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42661296/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42661296/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42661296/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42661296/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42661296/#conflict-of-interest) * [ Figures ](https://pubmed.ncbi.nlm.nih.gov/42661296/#figures) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42661296/#similar) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42661296/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42661296/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42661296/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42661296/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42661296/#related-links) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42661296/#grants) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42661296/#linkout) Title & authors Abstract Conflict of interest statement Figures Similar articles References Publication types MeSH terms Substances Related information Grants and funding LinkOut - more resources Review Diabetes Metab Res Rev Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Diabetes+Metab+Res+Rev%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Diabetes+Metab+Res+Rev%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42661296/) . 2026 Sep;42(6):e70224. doi: 10.1002/dmrr.70224. # B Lymphocytes in Latent Autoimmune Diabetes in Adults: From Autoimmune Activation to Immunometabolic Heterogeneity and Precision Therapeutic Perspectives [Moncef Zouali](https://pubmed.ncbi.nlm.nih.gov/?term=Zouali+M&cauthor_id=42661296)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42661296/#full-view-affiliation-1 "Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.") Affiliations Expand ### Affiliation * 1 Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan. * PMID: **42661296** * PMCID: [ PMC13522400 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC13522400/) * DOI: [ 10.1002/dmrr.70224 ](https://doi.org/10.1002/dmrr.70224) Item in Clipboard Review # B Lymphocytes in Latent Autoimmune Diabetes in Adults: From Autoimmune Activation to Immunometabolic Heterogeneity and Precision Therapeutic Perspectives Moncef Zouali. Diabetes Metab Res Rev. 2026 Sep. Show details Display options Display options Format Abstract PubMed PMID Diabetes Metab Res Rev Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Diabetes+Metab+Res+Rev%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Diabetes+Metab+Res+Rev%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42661296/) . 2026 Sep;42(6):e70224. doi: 10.1002/dmrr.70224. ### Author [Moncef Zouali](https://pubmed.ncbi.nlm.nih.gov/?term=Zouali+M&cauthor_id=42661296)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42661296/#short-view-affiliation-1 "Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.") ### Affiliation * 1 Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan. * PMID: **42661296** * PMCID: [ PMC13522400 ](https://pmc.ncbi.nlm.nih.gov/articles/PMC13522400/) * DOI: [ 10.1002/dmrr.70224 ](https://doi.org/10.1002/dmrr.70224) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID ## Abstract Latent autoimmune diabetes in adults (LADA) is a heterogeneous form of autoimmune diabetes characterised by adult onset, the presence of islet autoantibodies, and a slower progression to insulin dependence compared with classical type 1 diabetes. Positioned at the interface of type 1 and type 2 diabetes, LADA arises from complex interactions among genetic susceptibility, immune dysregulation, and metabolic stress. While autoreactive T cells are recognized as central mediators of β-cell destruction, accumulating evidence indicates that B lymphocytes play a broader and dynamic role in disease pathogenesis than previously appreciated. Beyond autoantibody production, B cells contribute to LADA through antigen presentation, cytokine secretion, and regulation of T cell responses, thereby amplifying autoimmune circuits within pancreatic islets. Emerging studies further demonstrate perturbations in circulating B cell subsets, including expansion of memory B cells and plasmablasts and impairment of regulatory B cells. However, whether these alterations represent primary drivers of disease progression or secondary responses to ongoing β-cell injury remains unresolved. In parallel, immunometabolic stress and β-cell dysfunction promote neoantigen formation and may shape B cell activation and selection, linking metabolic perturbations to adaptive immune dysregulation. Together, these findings support a model in which B lymphocytes act as both effector and regulatory components within a dynamic immunometabolic network that determines disease heterogeneity and progression. Recent advances in molecular profiling have further revealed distinct LADA endotypes, particularly stratified by glutamic acid decarboxylase antibody levels, suggesting divergent autoimmune and metabolic contributions across patient subgroups. These insights provide a rationale for precision medicine approaches and highlight B lymphocyte-targeted interventions as potential, although still investigational, therapeutic strategies aimed at preserving residual β-cell function. **Keywords:** immune tolerance; molecular endotypes; precision medicine; regulatory B cells; β‐cells. © 2026 The Author(s). Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement The author declares no conflicts of interest. ## Figures [ ![FIGURE 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/13522400/66f2b54c0606/DMRR-42-e70224-g001.gif) ](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/13522400/63aae57db816/DMRR-42-e70224-g001.webp) ** FIGURE 1 ** Immunometabolic circuit underlying LADA pathogenesis.… ** FIGURE 1 ** Immunometabolic circuit underlying LADA pathogenesis. LADA arises from a bidirectional interaction between genetic… **FIGURE 1** Immunometabolic circuit underlying LADA pathogenesis. LADA arises from a bidirectional interaction between genetic susceptibility, β‐cell stress, and immune dysregulation. Metabolic stress and inflammatory signalling induce endoplasmic reticulum dysfunction in pancreatic β‐cells, promoting neoantigen formation and enhanced antigen presentation. These stress‐induced changes facilitate activation of autoreactive B and T lymphocytes, initiating and sustaining a feed‐forward immune loop. Progressive immune‐mediated β‐cell injury further amplifies antigen release, reinforcing chronic inflammation and accelerating disease progression. B lymphocytes function as central immunological amplifiers in this process. They integrate β‐cell–derived antigenic signals and contribute to disease progression through antigen presentation to CD4+ T cells, autoantibody production, and cytokine secretion. These processes support the activation and maintenance of adaptive immune responses rather than serving as primary initiators of disease. [ ![FIGURE 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/13522400/99c7c3907c96/DMRR-42-e70224-g002.gif) ](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/13522400/e7e1b232d172/DMRR-42-e70224-g002.webp) ** FIGURE 2 ** Multifaceted roles of B lymphocytes… ** FIGURE 2 ** Multifaceted roles of B lymphocytes in LADA. Based on currently available evidence, B… **FIGURE 2** Multifaceted roles of B lymphocytes in LADA. Based on currently available evidence, B lymphocytes contribute to the pathogenesis of LADA through multiple interconnected functions that collectively amplify immune‐mediated β‐cell dysfunction. These include antigen presentation to CD4+ T cells via MHC class II, production of islet‐specific autoantibodies, and secretion of pro‐ and anti‐inflammatory cytokines. Alterations in B cell subsets, including expansion of memory B cells and plasmablasts and reduced regulatory B cell populations, are associated with heightened immune activation and reduced β‐cell function. Through these mechanisms, B lymphocytes integrate antigenic signals derived from stressed β‐cells and contribute to the maintenance and amplification of autoreactive T cell responses. This positions B lymphocytes as key immunological amplifiers within the immunometabolic network of LADA. [ ![FIGURE 3](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/13522400/40ca77c00e57/DMRR-42-e70224-g003.gif) ](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a1/13522400/ff8885bdc347/DMRR-42-e70224-g003.webp) ** FIGURE 3 ** Immunometabolic endotypes of LADA along… ** FIGURE 3 ** Immunometabolic endotypes of LADA along a GADA‐defined spectrum. LADA exhibits immunological and metabolic… **FIGURE 3** Immunometabolic endotypes of LADA along a GADA‐defined spectrum. LADA exhibits immunological and metabolic heterogeneity that can be conceptualised along a spectrum of glutamic acid decarboxylase antibody (GADA) titres, reflecting varying degrees of autoimmune and metabolic contributions rather than discrete disease subtypes. High‐GADA LADA is generally associated with stronger autoimmune activity, more pronounced B lymphocyte–mediated immune activation, and a more rapid decline in β‐cell function. This endotype is characterised by enhanced humoral immune responses and a greater contribution of immune‐mediated mechanisms. Low‐GADA LADA more frequently overlaps with metabolic features, such as insulin resistance, and displays comparatively weaker autoimmune signatures and slower progression of β‐cell dysfunction. These endotypes are not defined by absolute thresholds, but represent a continuum of immunometabolic activity shaped by interactions between β‐cell stress, immune activation, and metabolic dysregulation. B lymphocyte activity varies across this spectrum, contributing differentially to immune amplification and disease progression. The figure depicts a conceptual continuum and should not be interpreted as representing universally accepted GADA cutoffs. [See this image and copyright information in PMC](https://pubmed.ncbi.nlm.nih.gov/42661296/) ## Similar articles * [ Soluble LAG-3 Identifies a Dynamic Early T Cell Activation Window in self-reactivity, Type 1 Diabetes, and Broader Immune Responses. ](https://pubmed.ncbi.nlm.nih.gov/41726869/) Roy S, Proffer ML, Syed F, Smithmyer ME, Das Sharma A, Twoy A, Soo-Hoo E, Rana J, Spaeth JM, Meyer E, Jensen KP, Speake C, Hagopian W, Piganelli JD.Roy S, et al.bioRxiv [Preprint]. 2026 Apr 2:2026.02.10.705171. doi: 10.64898/2026.02.10.705171.bioRxiv. 2026.PMID: 41726869Free PMC article.Preprint. * [ Autoimmune aspects of type 2 diabetes mellitus - a mini-review. ](https://pubmed.ncbi.nlm.nih.gov/24457898/) Itariu BK, Stulnig TM.Itariu BK, et al.Gerontology. 2014;60(3):189-96. doi: 10.1159/000356747. Epub 2014 Jan 22.Gerontology. 2014.PMID: 24457898Review. * [ Personality Theories. ](https://pubmed.ncbi.nlm.nih.gov/42475469/) Gallios JM, Iyer V, Kaylor LE.Gallios JM, et al.2026 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.2026 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.PMID: 42475469Free Books & Documents. * [ Type 1 Diabetes: A Guide to Autoimmune Mechanisms for Clinicians. ](https://pubmed.ncbi.nlm.nih.gov/40375390/) Mauvais FX, van Endert PM.Mauvais FX, et al.Diabetes Obes Metab. 2025 Aug;27 Suppl 6(Suppl 6):40-56. doi: 10.1111/dom.16460. Epub 2025 May 15.Diabetes Obes Metab. 2025.PMID: 40375390Free PMC article.Review. * [ Changes of B cell subsets in different types of diabetes and its effect on the progression of latent autoimmune diabetes in adults. ](https://pubmed.ncbi.nlm.nih.gov/37755622/) Wu P, Song Y, Chen Z, Xia J, Zhou Y.Wu P, et al.Endocrine. 2024 Mar;83(3):624-635. doi: 10.1007/s12020-023-03539-9. Epub 2023 Sep 27.Endocrine. 2024.PMID: 37755622 [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42661296) ## References 1. 1. Naik R. G., Brooks‐Worrell B. M., and Palmer J. P., “Latent Autoimmune Diabetes in Adults,” Journal of Clinical Endocrinology & Metabolism 94, no. 12 (2009): 4635–4644, 10.1210/jc.2009-1120. - [DOI](https://doi.org/10.1210/jc.2009-1120) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/19837918/) 2. 1. Buzzetti R., Tuomi T., Mauricio D., et al., “Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel,” Diabetes 69, no. 10 (2020): 2037–2047, 10.2337/dbi20-0017. - [DOI](https://doi.org/10.2337/dbi20-0017) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC7809717/) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/32847960/) 3. 1. Cervin C., Lyssenko V., Bakhtadze E., et al., “Genetic Similarities Between Latent Autoimmune Diabetes in Adults, Type 1 Diabetes, and Type 2 Diabetes,” Diabetes 57, no. 5 (2008): 1433–1437, 10.2337/db07-0299. - [DOI](https://doi.org/10.2337/db07-0299) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/18310307/) 4. 1. Andersen M. K., Lundgren V., Turunen J. A., et al., “Latent Autoimmune Diabetes in Adults Differs Genetically From Classical Type 1 Diabetes Diagnosed After the Age of 35 Years,” Diabetes Care 33, no. 9 (2010): 2062–2064, 10.2337/dc09-2188. - [DOI](https://doi.org/10.2337/dc09-2188) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928363/) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/20805278/) 5. 1. Hernandez M., Novoa‐Medina Y., Faner R., et al., “Genetics: Is LADA Just Late Onset Type 1 Diabetes?,” Frontiers in Endocrinology (Lausanne) 13 (2022): 916698, 10.3389/fendo.2022.916698. - [DOI](https://doi.org/10.3389/fendo.2022.916698) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9404871/) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/36034444/) Show all 55 references ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubm
## Related Clinical Research

- [MCC950 Improves Glycemic Control, Lipids, and Sympathetic Markers in STZ-Induced Type 1 Diabetic R](https://medichelpline.com/clinical-feed/pubmed-42669910.md)
- [Omnipod 5 Automated Insulin Delivery: 12-Month Extension Outcomes in Adults with Type 1 Diabetes](https://medichelpline.com/clinical-feed/pubmed-42671087.md) (DOI: 10.1002/edm2.70321)
- [Antidiabetic regimens and risk of cognitive disorders in type 2 diabetes: large retrospective coho](https://medichelpline.com/clinical-feed/plos-one-23-antidiabetic-medications-and-risk-of-cognitive-disorders-in-type-2-diabetes-a.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [Social determinants of health and postnatal well-being in Thai women with type 2 diabetes: mixed‑m](https://medichelpline.com/clinical-feed/plos-one-8-social-determinants-of-health-and-postnatal-wellbeing-among-women-with-type-2.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.